Human Papillomavirus Vaccination for Men

Advancing Policy and Practice

Peter A Newman; Ashley Lacombe-Duncan


Future Virology. 2014;9(12):1033-1047. 

In This Article


This review suggests the importance of a comprehensive and critical consideration of the evidence used to support the status quo in most countries with publicly funded vaccination programs that subsidize HPV vaccination for girls, but not for boys. Based on the low HPV vaccine coverage in many countries, the unsuccessful history of other targeted vaccination programs, and the disproportionate disease burden and impact among medically underserved, and ethnic and sexual minority populations, these policies are likely to result in tens of thousands of new cancers in both men and women that might otherwise have been prevented; thus the onus should rightfully be placed on those who would maintain the status quo rather than those who advocate universal HPV vaccine coverage.

Concurrently, the pursuit of a number of promising directions for investigations to support the design and evaluation of interventions to increase HPV4 vaccine acceptability and uptake among boys and young men, including interventions to mitigate systemic barriers to uptake, and those designed for HCP and parents, may improve on the low HPV4 coverage among boys and young men in many settings. However, rather than a replacement for fundamentally important policy changes, evidence informed multilevel interventions to increase HPV vaccine acceptability and uptake for males can serve to further accelerate coverage once public subsidies are equitably allotted to support universal HPV vaccination programs for boys and girls, thereby maximizing population health.